Drug Profile
PS 460644
Alternative Names: PS460644Latest Information Update: 01 Aug 2007
Price :
$50
*
At a glance
- Originator Pharmacopeia Drug Discovery
- Developer Pharmacopeia
- Class
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Hypersensitivity
Most Recent Events
- 01 Aug 2007 Discontinued - Phase-I for Allergy (unspecified route)
- 01 Aug 2007 Discontinued - Phase-I for Asthma (unspecified route)
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc